Literature DB >> 21933230

Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS).

S R Janmohamed1, F B de Waard-van der Spek, G C Madern, P C J de Laat, W C J Hop, A P Oranje.   

Abstract

BACKGROUND: Haemangioma of infancy (HOI) is the most frequently occurring benign tumour of infancy. A good, reliable and objective scoring system for haemangioma activity is not yet available. AIM: We have developed a simple system called the Haemangioma Activity Score (HAS) for scoring the (disease) proliferative activity of haemangiomas. The current study was undertaken to validate this system.
METHODS: We validated the HAS in a comparative study of photographs taken during consultations from 2000 until 2008 (n = 78). Agreement between three observers was assessed at two different time points (t(0) and t(1)) with a minimum interval of 6 months between them, using interclass correlation coefficients (ICC).
RESULTS: Agreement between observers was good. The average ICC of the HAS at t(0) and t(1) was 0.72 and 0.76, respectively. The average ICC of the HAS for the changes from baseline (HAS at t(0) minus HAS at t(1) ) was 0.69.
CONCLUSIONS: We conclude that the HAS is a good system for scoring the proliferative activity of haemangiomas, and believe it to be useful in future investigations. The number of studies comparing different therapies for treating haemangiomas is steadily increasing, and the HAS (before and after treatment) may provide a valuable scoring system for evaluating such therapies. © The Author(s). CED
© 2011 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2011        PMID: 21933230     DOI: 10.1111/j.1365-2230.2011.04080.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  10 in total

Review 1.  Educational paper: therapy of infantile haemangioma--history and current state (part II).

Authors:  Sherief R Janmohamed; Gerard C Madern; Peter C J de Laat; Arnold P Oranje
Journal:  Eur J Pediatr       Date:  2014-09-03       Impact factor: 3.183

2.  Haemangioma of infancy: two case reports with an overdose of propranolol.

Authors:  S R Janmohamed; G C Madern; P C J de Laat; A P Oranje
Journal:  Case Rep Dermatol       Date:  2011-02-05

3.  Evaluation of intra-lesional corticosteroids in the treatment of peri-ocular haemangioma of infancy: still an alternative besides propranolol.

Authors:  Sherief R Janmohamed; Gerard C Madern; Klaske Nieuwenhuis; Peter C J de Laat; Arnold P Oranje
Journal:  Pediatr Surg Int       Date:  2011-12-27       Impact factor: 1.827

4.  The Effect of Oral Propranolol versus Oral Corticosteroids in Management of Pediatric Hemangiomas.

Authors:  Adil Ali; Umme Aiman; Mohd Azam Haseen; Mohd Altaf Mir; Imran Ghani; Ragya Bharadwaj; Mohd Yaseen
Journal:  World J Plast Surg       Date:  2018-01

5.  Infantile Hemangiomas with Minimal and Arrested Growth: Clinical Features and Treatment Outcomes with 0.5% Topical Timolol Maleate.

Authors:  Kyung-Nam Bae; Kihyuk Shin; Hoon-Soo Kim; Byung-Soo Kim; Moon-Bum Kim; Hyun-Chang Ko
Journal:  Ann Dermatol       Date:  2021-09-08       Impact factor: 1.444

6.  Cost-effectiveness of atenolol compared to propranolol as first-line treatment of infantile haemangioma: A pilot study.

Authors:  Sasha Wilson; Deniz Hassan; Molly Jakeman; Eleonore Breuning
Journal:  JPRAS Open       Date:  2022-05-26

7.  Infantile Hemangioma Treated with Propranolol Readmission Trends, Complications of Therapy, and Cost: A PHIS Database Study.

Authors:  Muhammad Abu-Rmaileh; Hayden C Hairston; Isabella Zaniletti; Anvesh Kompelli; Kyle P Davis; James Reed Gardner; Elijah H Bolin; Gresham T Richter
Journal:  Int J Pediatr       Date:  2022-09-09

8.  Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study.

Authors:  Martin Theiler; Nicole Knöpfel; Susanne von der Heydt; Agnes Schwieger-Briel; Isabelle Luchsinger; Alexandra Smith; Kristin Kernland-Lang; Regula Waelchli; Kathrin Neuhaus; Malcolm Kohler; Ralph Gnannt; Sarah F Schoch; Lisa Weibel; Salome Kurth
Journal:  Eur J Pediatr       Date:  2021-06-18       Impact factor: 3.183

9.  Oral atenolol therapy for proliferating infantile hemangioma: A prospective study.

Authors:  Yi Ji; Qi Wang; Siyuan Chen; Bo Xiang; Zhicheng Xu; Yuan Li; Lin Zhong; Xiaoping Jiang; Xiaodong Yang
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  Utility of the Infantile Hemangioma Referral Score (IHReS) as a decision-making tool for referral to treatment.

Authors:  Kanokporn Chitpiromsak; Leelawadee Techasatian; Charoon Jetsrisuparb
Journal:  BMJ Paediatr Open       Date:  2021-09-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.